NCT07036458View on ClinicalTrials.gov

To Evaluate the Mass Balance Recovery, Metabolite Profile and Metabolite Identification in Healthy Male Subjects

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

August 22, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

January 9, 2026

Conditions

Healthy Male Adults

Interventions

DRUG

14C Epaminurad Oral Solution

Subjects will receive a single administration of 14C Epaminurad Oral Solution

Trial Locations (1)

Unknown

Quotient Science, Nottingham

Sponsors

Lead Sponsor

JW Pharmaceutical

All Listed Sponsors

lead

JW Pharmaceutical

INDUSTRY